Bristol-Myers Squibb Company beats revenue forecasts & raises 2025 guidance. Click for key BMY catalysts, risks, and outlook ...

On July 31, the Trump administration told 17 major drugmakers to align U.S. medication prices with the lowest prices sold in other countries, or the most-favored-nation price.  The White House ...

Bristol-Myers Squibb (BMY) shares rebound after recent losses. Analysts weigh in on its value, growth potential, and updated ...

Experts are skeptical that Big Pharma companies will cut prices after President Donald Trump demands Most Favored Nation policies within 60 days.

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

Bullish option flow detected in Bristol Myers ( BMY) Squibb with 19,247 calls trading, 3x expected, and implied vol ...

The Health Resources and Services Administration has opened applications for a voluntary pilot program aimed at evaluating the 340B rebate model.  The 340B Program traditionally has offered up-front ...

World shares retreated Friday after President Donald Trump issued a new set of import duties that will apply to dozens of ...

Mayo Clinic has treated the first person in the U.S. using a novel radioactive medicine for advanced breast cancer as part of ...

Rounding up five deals in the home healthcare sector, which has caught the attention of Accel-KKR, Berkshire Partners, ...